Skip to main content
Clinical Trials/NCT06036446
NCT06036446
Recruiting
Not Applicable

Cervical Cerclage for Short Cervix at 24-26 Weeks of Gestation: a Randomized Controlled Trial

Thomas Jefferson University1 site in 1 country329 target enrollmentNovember 10, 2023

Overview

Phase
Not Applicable
Intervention
Cervical cerclage
Conditions
Premature Birth
Sponsor
Thomas Jefferson University
Enrollment
329
Locations
1
Primary Endpoint
Incidence of preterm birth <37 weeks
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to determine whether cervical cerclage reduces the risk of preterm birth in patients with a short transvaginal ultrasound (TVU) cervical length (CL) ≤25mm between 24 0/7-26 6/7 weeks.

Detailed Description

Singleton high-risk pregnancies \< 24 weeks of gestation will be screened for enrollment and randomized, if a short TVU CL (≤25mm) is detected between 24 0/7 - 26 6/7 weeks, to either cervical cerclage or control (no cerclage). Aside from cerclage placement, management of included women will be the same including recommendation for continuing or initiating daily vaginal progesterone 200mg from randomization until 36 6/7 weeks. The primary outcome will be the incidence of preterm birth \<37 weeks.

Registry
clinicaltrials.gov
Start Date
November 10, 2023
End Date
February 2029
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18-50 years old, pregnant, assigned female at birth
  • Singleton pregnancy
  • TVU CL ≤25mm between 24 0/7 - 26 6/7 weeks of gestation

Exclusion Criteria

  • Initial multifetal gestation with subsequent multifetal pregnancy reduction, or selective fetal termination performed \>14 weeks, or cotwin pregnancy loss diagnosed \>14 weeks
  • Cerclage in situ
  • Preterm labor, defined as painful regular uterine contractions and change in cervical dilation
  • Active vaginal bleeding
  • Suspected intraamniotic infection
  • Major fetal structural abnormality or chromosomal disorder
  • Placenta previa or accreta
  • Other contraindication to cerclage placement
  • Participation in another clinical trial related to preterm birth prevention, cerclage, or progesterone

Arms & Interventions

Cerclage

Cervical cerclage placement with removal during the 36th week of gestation or earlier if clinically indicated.

Intervention: Cervical cerclage

Cerclage

Cervical cerclage placement with removal during the 36th week of gestation or earlier if clinically indicated.

Intervention: Vaginal Suppository Progesterone

Control

Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.

Intervention: Vaginal Suppository Progesterone

Outcomes

Primary Outcomes

Incidence of preterm birth <37 weeks

Time Frame: At delivery

Secondary Outcomes

  • Time interval from randomization to delivery(At delivery)
  • Incidence of preterm birth <34 weeks, <32 weeks, and <28 weeks(At delivery)
  • Gestational age at delivery(At delivery)
  • Incidence of preterm prelabor rupture of membranes (PPROM)(At occurrence up to 36 weeks and 6 days of gestation)
  • Incidence of intraamniotic infection(At the time of delivery at any gestational age)
  • Neonatal outcomes: incidence of low birthweight (<2500g)(At delivery)
  • Neonatal outcomes: incidence of very low birthweight (<1500g)(At delivery)
  • Neonatal outcomes: incidence of admission to neonatal intensive care unit(At delivery)
  • Neonatal outcomes: composite outcome of incidence of either respiratory distress syndrome, bronchopulmonary dysplasia, grade 3 or 4 intraventricular hemorrhage, necrotizing enterocolitis, culture confirmed sepsis, stillbirth, and neonatal mortality(At least 30 days after delivery, up to 6 months after delivery for outcomes except neonatal mortality)

Study Sites (1)

Loading locations...

Similar Trials